Abstracts tagged "certolizumab pegol and non-radiographic"

Abstract Number: 936 • 2019 ACR/ARP Annual Meeting
Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes
Jonathan Kay¹, Lianne Gensler ², Atul Deodhar ³, Walter P. Maksymowych ⁴, Nigil Haroon ⁵, Simone Auteri ⁶, Natasha de Peyrecave ⁷, Thomas Kumke ⁸, Bengt Hoepken ⁹, Lars Bauer ⁹ and Martin Rudwaleit ¹⁰, ¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁵Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim, Germany, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany
Background/Purpose: Patients (pts) with axial spondyloarthritis (axSpA) often experience delayed diagnosis, which can lead to treatment delay. However, there are indications that earlier treatment with…
Abstract Number: 687 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Atul A. Deodhar¹, Maxime Dougados², Robert Landewé³, Joachim Sieper⁴, Walter Maksymowych⁵, Martin Rudwaleit⁶, Filip van Den Bosch⁷, Jürgen Braun⁸, Philip J Mease⁹, Alan Kivitz¹⁰, Jessica Walsh¹¹, Owen Davies¹², Bengt Hoepken¹³, Luke Peterson¹⁴ and Désirée van der Heijde¹⁵, ¹Divison of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Academic Medical Center, Amsterdam and Zuyderland Medical Center, Heerlen, Netherlands, ⁴Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Klinikum Bielefeld and Charité – University Medicine Berlin, Berlin, Germany, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ⁹Swedish Medical Center and University of Washington, Seattle, WA, ¹⁰Altoona Center for Clinical Research, Duncansville, PA, ¹¹Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Monheim, Germany, ¹⁴UCB Pharma, Raleigh, NC, ¹⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RAPID-axSpA (NCT01087762) investigated the efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].